GlycoMimetics, Inc.
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2003-01-01
- Employees
- 51
- Market Cap
- $11.6M
- Website
- http://www.glycomimetics.com
A Study to Determine Safety and Tolerability of GMI-1359 in Subjects With HR+ Metastatic Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2019-12-13
- Last Posted Date
- 2022-03-22
- Lead Sponsor
- GlycoMimetics Incorporated
- Target Recruit Count
- 4
- Registration Number
- NCT04197999
- Locations
- 🇺🇸
Duke University Medical Center, Durham, North Carolina, United States
Study to Determine the Efficacy of Uproleselan (GMI-1271) in Combination With Chemotherapy to Treat Relapsed/Refractory Acute Myeloid Leukemia
- First Posted Date
- 2018-08-06
- Last Posted Date
- 2024-07-29
- Lead Sponsor
- GlycoMimetics Incorporated
- Target Recruit Count
- 388
- Registration Number
- NCT03616470
- Locations
- 🇺🇸
Rush University Medical Center, Chicago, Illinois, United States
🇺🇸Cleveland Clinic, Cleveland, Ohio, United States
🇺🇸Seattle Cancer Care Alliance, Seattle, Washington, United States
A Study in Healthy Volunteers to Investigate How Much Test Medicine [14C]-Uproleselan is Taken up by the Body When Administered Directly Into the Vein (IV)
- First Posted Date
- 2018-07-30
- Last Posted Date
- 2019-05-14
- Lead Sponsor
- GlycoMimetics Incorporated
- Target Recruit Count
- 5
- Registration Number
- NCT03606447
- Locations
- 🇬🇧
Quotient Sciences Limited, Ruddington, Nottingham, United Kingdom
A Study to Evaluate the Effect of Age on the Pharmacokinetics, Safety and Tolerability of IV Rivipansel.
- First Posted Date
- 2016-12-20
- Last Posted Date
- 2020-06-18
- Lead Sponsor
- GlycoMimetics Incorporated
- Target Recruit Count
- 16
- Registration Number
- NCT02998099
- Locations
- 🇺🇸
Orlando Clinical Research Center, Orlando, Florida, United States
Placebo-Controlled Single Dose Study to Evaluate Safety and Pharmacokinetics of GMI-1359 in Healthy Volunteers
- First Posted Date
- 2016-10-12
- Last Posted Date
- 2019-03-04
- Lead Sponsor
- GlycoMimetics Incorporated
- Target Recruit Count
- 58
- Registration Number
- NCT02931214
- Locations
- 🇺🇸
Celerion, Lincoln, Nebraska, United States
A Study to Evaluate the Effect of IV Doses of Rivipansel in Subjects With Moderate Hepatic Impairment and in Healthy Subjects With Normal Hepatic Function
- Conditions
- Interventions
- First Posted Date
- 2016-08-18
- Last Posted Date
- 2020-07-09
- Lead Sponsor
- GlycoMimetics Incorporated
- Target Recruit Count
- 16
- Registration Number
- NCT02871570
- Locations
- 🇺🇸
Orlando Clincial Research Center, Orlando, Florida, United States
A Study to Evaluate the Effect of IV Doses of Rivipansel on Subjects With Renal Impairment and in Healthy Subjects
- First Posted Date
- 2016-06-27
- Last Posted Date
- 2020-06-18
- Lead Sponsor
- GlycoMimetics Incorporated
- Target Recruit Count
- 28
- Registration Number
- NCT02813798
- Locations
- 🇺🇸
Anaheim Clinical Trials, LLC, Anaheim, California, United States
🇺🇸Avail Clinical Research, LLC, DeLand, Florida, United States
🇺🇸Orlando Clinical Research Center, Orlando, Florida, United States
A Study to Determine the Efficacy, Safety and Pharmacokinetics of GMI-1271 as Adjunct to Standard of Care for the Treatment of Multiple Myeloma
- First Posted Date
- 2016-06-23
- Last Posted Date
- 2019-07-10
- Lead Sponsor
- GlycoMimetics Incorporated
- Target Recruit Count
- 10
- Registration Number
- NCT02811822
- Locations
- 🇬🇧
Saint James's University Hospital Leeds, Leeds, United Kingdom
🇩🇪Medizinische Klinik/Abt. Innere Medizin V, Heidelberg, Germany
🇮🇪Cork University Hospital, Wilton, Cork, Ireland
Study to Assess Safety, Tolerability, and Efficacy of GMI-1271 in Patients With Calf-level Deep Venous Thrombosis (DVT)
- Conditions
- Interventions
- First Posted Date
- 2016-04-20
- Last Posted Date
- 2019-06-14
- Lead Sponsor
- GlycoMimetics Incorporated
- Target Recruit Count
- 2
- Registration Number
- NCT02744833
- Locations
- 🇺🇸
University of Michigan, Ann Arbor, Michigan, United States
A Study to Evaluate the PK, Safety and Tolerability of GMI-1271 With and Without Filgrastim in Healthy Adult Subjects
- Conditions
- Interventions
- First Posted Date
- 2016-03-09
- Last Posted Date
- 2018-02-27
- Lead Sponsor
- GlycoMimetics Incorporated
- Target Recruit Count
- 54
- Registration Number
- NCT02703051
- Locations
- 🇺🇸
Celerion, Lincoln, Nebraska, United States